{"disease":{"id":"solid-tumor-adult","name":"solid tumor adult"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06895681","title":"UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04932525","title":"Gustave Roussy Cancer Profiling","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT03324841","title":"POA Prospective Repository","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Caris Science, Inc.","has_results":false},{"nct_id":"NCT03326479","title":"POA Retrospective Repository","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Caris Science, Inc.","has_results":false},{"nct_id":"NCT05695638","title":"Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Morten Ladekarl","has_results":false},{"nct_id":"NCT05416710","title":"Universal Germline Testing in the Community","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Invitae Corporation","has_results":false},{"nct_id":"NCT05216432","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":930,"lead_sponsor_name":"Relay Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04811781","title":"Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study","phase":"","overall_status":"COMPLETED","enrollment_count":761,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04739696","title":"Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":510,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT03929653","title":"Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT06350539","title":"Personalized Models for Cancer Research","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT04526106","title":"REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Elevar Therapeutics","has_results":false},{"nct_id":"NCT04665206","title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":434,"lead_sponsor_name":"Vivace Therapeutics, Inc","has_results":false},{"nct_id":"NCT07417189","title":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":401,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT04913285","title":"A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":false},{"nct_id":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT03410121","title":"Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Center Eugene Marquis","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT06265727","title":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":348,"lead_sponsor_name":"Corbus Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04983810","title":"A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Cyclacel Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06090513","title":"Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bien-Willner Physicians Group PA","has_results":false},{"nct_id":"NCT06404528","title":"Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Wuxi People's Hospital","has_results":false},{"nct_id":"NCT06380660","title":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":298,"lead_sponsor_name":"Acerand Therapeutics (Shanghai) Limited","has_results":false},{"nct_id":"NCT04402606","title":"Study on Skin Toxicities Induced by Cancer Treatments","phase":"NA","overall_status":"COMPLETED","enrollment_count":292,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT04537936","title":"Psychotherapy Intervention for Latinos With Adv Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":285,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04143711","title":"Study of DF1001 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Dragonfly Therapeutics","has_results":false},{"nct_id":"NCT04725474","title":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"CatalYm GmbH","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT04353375","title":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":235,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT04942717","title":"Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values","phase":"NA","overall_status":"RECRUITING","enrollment_count":234,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04976803","title":"Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein","phase":"","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Artios Pharma Ltd","has_results":false},{"nct_id":"NCT04650451","title":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":220,"lead_sponsor_name":"Bellicum Pharmaceuticals","has_results":false},{"nct_id":"NCT06088004","title":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":218,"lead_sponsor_name":"Suzhou Abogen Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT03161821","title":"Circulating Tumor Cells in Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04130516","title":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Linnaeus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05230186","title":"A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04165772","title":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06916442","title":"Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT06292845","title":"Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03520075","title":"Study of ASTX029 in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT04621435","title":"Imaging of Solid Tumors Using FAP-2286","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":191,"lead_sponsor_name":"Thomas Hope","has_results":false},{"nct_id":"NCT04015609","title":"Psychotherapy Intervention for Latinos With Advanced Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07396584","title":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT05131113","title":"Stratification of Patients in Oncogeriatrics and Personalization of Interventions","phase":"NA","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Biogipuzkoa Health Research Institute","has_results":false},{"nct_id":"NCT04306900","title":"TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Trishula Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03084757","title":"SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)","phase":"NA","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT04705818","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT03761017","title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"MacroGenics","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}